Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
Adverse effects: local · people with eczema
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
Weekend therapy may leads to lower local adverse events: skin thinning; end of treatment (16‐20 weeks +… compared with no topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema
It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).
1 finding from 1 review